Tags

Type your tag names separated by a space and hit enter

Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer.
Drugs 2019D

Abstract

Approximately 70% of breast cancers are estrogen-receptor positive. Tamoxifen and aromatase inhibitors have been the mainstay of endocrine therapy and have improved breast cancer survival. However, a large number of patients experience disease recurrence either during or following completion of endocrine therapy. Recent improvements in our understanding of the various mechanisms underlying the development of endocrine resistance have led to a dramatic change in the landscape of current endocrine treatment with the introduction of new drugs targeting molecular pathways involved in endocrine resistance. Over the past years we have witnessed the use of combination endocrine therapy with mammalian target of rapamycin antagonists, whilst most recently the introduction of cyclin-dependent kinase 4/6 inhibitors has significantly improved response to endocrine therapy. Whilst not a formal systematic review, this article will provide historical background and summarise key clinical trials and current strategies in both first-line and second-line endocrine therapy.

Authors+Show Affiliations

Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK.Department of Medicine, Royal Marsden NHS Foundation Trust, Fulham Road, Chelsea, London, SW3 6JJ, UK. stephen.johnston@rmh.nhs.uk.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

31630379

Citation

Aggelis, Vassilis, and Stephen R D. Johnston. "Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer." Drugs, 2019.
Aggelis V, Johnston SRD. Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs. 2019.
Aggelis, V., & Johnston, S. R. D. (2019). Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs, doi:10.1007/s40265-019-01208-8.
Aggelis V, Johnston SRD. Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. Drugs. 2019 Oct 19; PubMed PMID: 31630379.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer. AU - Aggelis,Vassilis, AU - Johnston,Stephen R D, Y1 - 2019/10/19/ PY - 2019/10/21/entrez PY - 2019/10/21/pubmed PY - 2019/10/21/medline JF - Drugs JO - Drugs N2 - Approximately 70% of breast cancers are estrogen-receptor positive. Tamoxifen and aromatase inhibitors have been the mainstay of endocrine therapy and have improved breast cancer survival. However, a large number of patients experience disease recurrence either during or following completion of endocrine therapy. Recent improvements in our understanding of the various mechanisms underlying the development of endocrine resistance have led to a dramatic change in the landscape of current endocrine treatment with the introduction of new drugs targeting molecular pathways involved in endocrine resistance. Over the past years we have witnessed the use of combination endocrine therapy with mammalian target of rapamycin antagonists, whilst most recently the introduction of cyclin-dependent kinase 4/6 inhibitors has significantly improved response to endocrine therapy. Whilst not a formal systematic review, this article will provide historical background and summarise key clinical trials and current strategies in both first-line and second-line endocrine therapy. SN - 1179-1950 UR - https://www.unboundmedicine.com/medline/citation/31630379/Advances_in_Endocrine-Based_Therapies_for_Estrogen_Receptor-Positive_Metastatic_Breast_Cancer L2 - https://dx.doi.org/10.1007/s40265-019-01208-8 DB - PRIME DP - Unbound Medicine ER -